Treatment of Rare Epithelial Ovarian Tumors

Lauren P Cobb; David M Gershenson

doi:10.1016/j.hoc.2018.07.015

Treatment of Rare Epithelial Ovarian Tumors

Hematol Oncol Clin North Am. 2018 Dec;32(6):1011-1024. doi: 10.1016/j.hoc.2018.07.015.

Authors

Lauren P Cobb¹, David M Gershenson²

Affiliations

¹ Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Pressler, Unit 1362, Houston, TX 77030, USA. Electronic address: LPCobb@mdanderson.org.
² Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Pressler, Unit 1362, Houston, TX 77030, USA.

PMID: 30390757
DOI: 10.1016/j.hoc.2018.07.015

Abstract

Traditionally, the management of epithelial ovarian cancer has been approached using a one-size-fits-all mentality. This strategy does not acknowledge the differences in epidemiology and clinical behavior of many of the histologic and molecular subgroups of ovarian cancer, specifically the rare histologies. While cytoreductive surgery followed by adjuvant platinum and taxane-based chemotherapy is the mainstay of primary treatment of epithelial ovarian cancer as a group, further investigation of novel therapeutics is critical for improving outcomes of these rare histologies. This article focuses on the management of non-high grade serous histologies of ovarian cancer.

Keywords: Carcinosarcoma; Clear cell carcinoma; Endometrioid carcinoma; Epithelial ovarian carcinoma; Low-grade serous carcinoma; Mucinous carcinoma; Small cell carcinoma of the ovary; Treatment.

Publication types

Review

MeSH terms

Carcinoma, Ovarian Epithelial* / classification
Carcinoma, Ovarian Epithelial* / diagnosis
Carcinoma, Ovarian Epithelial* / metabolism
Carcinoma, Ovarian Epithelial* / therapy
Female
Humans
Ovarian Neoplasms* / classification
Ovarian Neoplasms* / diagnosis
Ovarian Neoplasms* / metabolism
Ovarian Neoplasms* / therapy